Mode
Text Size
Log in / Sign up
N/A N=44 Treatment

Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos

Unwanted Tattoos

Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Tattoo Clearance Percentage Using a Photographic Scale — 84.7 percentage of clearance

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Picosure Laser System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cynosure, Inc.
Primary completion
Jan 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Tattoo Clearance Percentage Using a Photographic Scale
84.7
SECONDARY
Investigator Satisfaction
0; 1; 19; 14
SECONDARY
Subject Satisfaction
1; 5; 17; 11

Summary

The purpose of this study is to evaluate the PICOSURE Laser System for the treatment of unwanted tattoos

Eligibility Criteria

Inclusion Criteria

  • Is a healthy non-smoking (must have quit 6 months prior) male or female between 18 and 65 years old.
  • Is willing to consent to participate in the study.
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits
  • Has unwanted non-cosmetic tattoo containing red ink, that has not previously been treated, and wishes to undergo laser treatment

Exclusion Criteria

  • The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  • The subject is hypersensitive to light exposure OR takes photo sensitized medication.
  • The subject has active or localized systemic infections.
  • The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy {greater than 81 mg per day}).
  • The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  • The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study.
  • The subject has used Accutane within 6 months prior to enrollment.
  • The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
  • The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
  • The subject has a history of keloids.
  • The subject has evidence of compromised wound healing.
  • The subject has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.
  • The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02103153). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search